Merit Medical Systems (MMSI) Stock Overview
Designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States, China, Japan, Germany, France, the United Kingdom, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
MMSI passed our risk checks.
MMSI Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Merit Medical Systems, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$83.35 |
| 52 Week High | US$94.75 |
| 52 Week Low | US$59.74 |
| Beta | 0.51 |
| 1 Month Change | 20.20% |
| 3 Month Change | 34.41% |
| 1 Year Change | -1.78% |
| 3 Year Change | 15.44% |
| 5 Year Change | 24.42% |
| Change since IPO | 1,507.79% |
Recent News & Updates
MMSI: Lower P/E Assumptions Will Set Up Future Repricing Potential
The analyst price target for Merit Medical Systems has been reduced from about $118 to $110 as analysts incorporate a slightly lower assumed future P/E multiple, while maintaining modestly higher revenue growth and profit margin assumptions. Analyst Commentary Recent Street research on Merit Medical Systems has centered on lower price targets, but many reports still highlight constructive views on the company’s execution and long term opportunity set.
MMSI: Discount Rate Reset And 2026 Guidance Will Support Share Price
Analysts have trimmed their price targets on Merit Medical Systems by between $2 and $20, with the updated fair value estimate holding near $89.55 as they adjust assumptions around discount rates and valuation multiples while keeping revenue growth and profit margin expectations broadly unchanged. Analyst Commentary Recent Street research around Merit Medical Systems shows a cluster of reduced price targets, but the commentary behind those changes is more mixed.MMSI: Margin Strength And 2026 Guidance Reset Will Drive Future Upside
Merit Medical Systems' analyst price target has been reset lower by about $8.82 per share. This change reflects analysts' updated assumptions for slightly softer revenue growth, a modestly lower discount rate, stronger profit margins, and a reduced future P/E multiple.Recent updates
MMSI: Lower P/E Assumptions Will Set Up Future Repricing Potential
The analyst price target for Merit Medical Systems has been reduced from about $118 to $110 as analysts incorporate a slightly lower assumed future P/E multiple, while maintaining modestly higher revenue growth and profit margin assumptions. Analyst Commentary Recent Street research on Merit Medical Systems has centered on lower price targets, but many reports still highlight constructive views on the company’s execution and long term opportunity set.MMSI: Discount Rate Reset And 2026 Guidance Will Support Share Price
Analysts have trimmed their price targets on Merit Medical Systems by between $2 and $20, with the updated fair value estimate holding near $89.55 as they adjust assumptions around discount rates and valuation multiples while keeping revenue growth and profit margin expectations broadly unchanged. Analyst Commentary Recent Street research around Merit Medical Systems shows a cluster of reduced price targets, but the commentary behind those changes is more mixed.MMSI: Margin Strength And 2026 Guidance Reset Will Drive Future Upside
Merit Medical Systems' analyst price target has been reset lower by about $8.82 per share. This change reflects analysts' updated assumptions for slightly softer revenue growth, a modestly lower discount rate, stronger profit margins, and a reduced future P/E multiple.Oncology And Endoscopy Platforms Will Reshape Long Term Earnings Power
Catalysts About Merit Medical Systems Merit Medical Systems develops and sells medical devices used in vascular, oncology, cardiac, renal and endoscopy procedures worldwide. What are the underlying business or industry changes driving this perspective?Merit Medical Systems: Creating More Growth Engines (Rating Upgrade)
Summary Merit Medical Systems trades at 17-18x earnings with solid fundamentals, moderate leverage, and reasonable valuation, supporting an upbeat outlook. Q1 organic growth was on the lower end, but full-year guidance was maintained and even slightly raised for sales, reflecting recent M&A contributions. Growth engines include the View Point Medical acquisition and WRAPSODY, both expected to accelerate revenue and margin expansion into 2026. Despite softer organic growth and CEO transition, Merit's business remains resilient, with potential for re-rating as growth drivers materialize. Read the full article on Seeking Alpha
Tariffs And OEM Volatility Will Pressure Margins Yet Long Term Procedure Demand Will Support Progress
Catalysts About Merit Medical Systems Merit Medical Systems develops and sells medical devices used in vascular, oncology, cardiac, renal and endoscopy procedures worldwide. What are the underlying business or industry changes driving this perspective?MMSI: 2026 Guidance Execution And Margin Resilience Will Drive Future Upside
Analysts have nudged their price targets on Merit Medical slightly lower, with the updated fair value estimate moving from about $101.18 to $98.36 as they factor in modestly softer profit margin assumptions and a somewhat higher future P/E multiple, alongside recent target cuts and a downgrade tied to 2026 guidance uncertainty. Analyst Commentary Recent research on Merit Medical Systems highlights a mix of confidence in the business model and caution around execution against medium term targets, especially the 2026 outlook.MMSI: 2026 Margin Outlook And Guidance Will Drive Upside Potential
Analysts have trimmed the blended fair value estimate for Merit Medical Systems to about $101 from roughly $104, reflecting a lower projected price target that incorporates higher discount rates, slightly softer revenue growth assumptions, and a more moderate future P/E multiple, even as margin expectations improve. Analyst Commentary Recent Street research on Merit Medical Systems presents a mixed picture, with some analysts trimming targets or ratings on guidance uncertainty, while others still see room for valuation support based on execution and margins.We Like These Underlying Return On Capital Trends At Merit Medical Systems (NASDAQ:MMSI)
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Merit Medical: A Success Story That Keeps Getting Better
Summary Merit Medical continues to outperform, with the share price supported by on-target financial results, incremental M&A, and positive clinical data. The company's Wrapsody stent graft showed almost best-case clinical efficacy, positioning it to capture significant market share in dialysis graft occlusion procedures. Recent acquisitions, including EsophyX Z+ and Cook Medical’s lead management portfolio, enhance Merit’s product portfolio and offer longer-term synergies. CEO succession remains a concern, but could also prompt a bid for the company. Despite not being "super cheap", Merit’s strong execution, revenue growth, and margin leverage justify a positive rating, with potential for further valuation uplift. Read the full article on Seeking AlphaMerit Medical Systems: Solid Execution, Stretched Valuations
Summary Merit Medical Systems' stock is up 40% from last spring's lows, driven by strong Q3 results and positive analyst sentiment. The stock's rally has stalled recently. The company has also made a small acquisition in September and garnered a key FDA approval to close out 2024 on a high note. More upside ahead, or will the shares experience further profit-taking? An analysis of Merit Medical Systems follows in the paragraphs below. Read the full article on Seeking AlphaMerit Medical Systems - Impressive Momentum
Summary Merit Medical Systems has shown strong operating momentum this year, driven by organic growth and strategic acquisitions. Founder Fred Lampropoulos plans to retire by the end of 2025, as a well-planned succession alleviates concerns on that front. Recent acquisitions, including EndoGastric Solutions and Cook's Medical portfolio, enhance product offerings but are priced into the current high valuation. Despite positive momentum and trial results, the stock's high valuation warrants a cautious, wait-and-see approach. Read the full article on Seeking AlphaShareholder Returns
| MMSI | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 14.0% | 7.3% | -2.6% |
| 1Y | -1.8% | -15.9% | 14.3% |
Return vs Industry: MMSI exceeded the US Medical Equipment industry which returned -15.9% over the past year.
Return vs Market: MMSI underperformed the US Market which returned 14.3% over the past year.
Price Volatility
| MMSI volatility | |
|---|---|
| MMSI Average Weekly Movement | 5.1% |
| Medical Equipment Industry Average Movement | 8.4% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: MMSI has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: MMSI's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 7,500 | Martha Aronson | www.merit.com |
Merit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States, China, Japan, Germany, France, the United Kingdom, and internationally. It operates through two segments, Cardiovascular and Endoscopy. The company offers micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention products comprising angiography, drainage, delivery systems, and embolotherapy products; oncology products, such as soft tissue biopsy products and accessories; cardiac intervention products consisting of cardiac access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention products; and spine products, including vertebral augmentation, radiofrequency ablation, and bone biopsy systems.
Merit Medical Systems, Inc. Fundamentals Summary
| MMSI fundamental statistics | |
|---|---|
| Market cap | US$4.82b |
| Earnings (TTM) | US$139.34m |
| Revenue (TTM) | US$1.54b |
Is MMSI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MMSI income statement (TTM) | |
|---|---|
| Revenue | US$1.54b |
| Cost of Revenue | US$791.39m |
| Gross Profit | US$751.05m |
| Other Expenses | US$611.71m |
| Earnings | US$139.34m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.34 |
| Gross Margin | 48.69% |
| Net Profit Margin | 9.03% |
| Debt/Equity Ratio | 45.2% |
How did MMSI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/30 23:40 |
| End of Day Share Price | 2026/07/30 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Merit Medical Systems, Inc. is covered by 22 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Baird |
| David Rescott | Baird |
| Michael Petusky | Barrington Research Associates, Inc. |